# Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC

> **NCT06861777** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **YIN LI** · enrollment: 474 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **OTHER:** Adebrelimab + paclitaxel/nab-paclitaxel + cisplatin followed by chemoradiotherapy
- **OTHER:** chemoradiotherapy followed by adebrelimab + paclitaxel/nab-paclitaxel + cisplatin
- **OTHER:** TNT treatment [TNT group one (phase 2) or TNT group two (phase 2)]
- **OTHER:** Chemoradiotherapy

## Key facts

- **NCT ID:** NCT06861777
- **Lead sponsor:** YIN LI
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2031-05
- **Final completion:** 2031-05
- **Target enrollment:** 474 (ESTIMATED)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06861777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06861777, "Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06861777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*